Current status and perspectives in Joint Clinical Assessment

While the first two joint clinical assessments were launched in April 2025, a document published by the European Medicines Agency and the Heads of HTA Agencies Group addresses the remaining issues to reduce uncertainty in the parallel joint assessment of the first categories of medicines and medical devices covered by the HTA Regulation

The EU’s Competitiveness Compass and the new EU Biotech Hub

The Competitiveness Compass describes the new European Commission’s political actions to fill the gap with international competitors, support the transition to clean and digital technologies, and reduce supply chains’ dependencies in strategic sectors. Among these are also biotechnologies and more extensively, life sciences.